$HLYK
HealthLynked Corp Stock $hlyk

$hlyk Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-K Financial Statement

#000121390024028696 Filed on April 01, 2024

Income Statement

Concept	2024 Q2	2023 Q4	2023
Revenue	$795.1K	$931.2K	$5.722M
YoY Change	-53.33%	-19.38%	-2.32%
Cost Of Revenue	$414.0K	$440.8K	$2.348M
YoY Change	-39.18%	-38.19%	-22.51%
Gross Profit	$381.1K	$490.4K	$3.375M
YoY Change	-62.74%	10.96%	19.3%
Gross Profit Margin	47.94%	52.67%	58.98%
Selling, General & Admin	$861.5K	$1.514M	$3.623M
YoY Change	3.33%	-19.87%	-20.84%
% of Gross Profit	226.03%	308.77%	107.37%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$29.53K	$88.27K	$352.0K
YoY Change	-66.55%	-57.39%	-57.56%
% of Gross Profit	7.75%	18.0%	10.43%
Operating Expenses	$1.875M	$1.603M	$3.623M
YoY Change	-25.06%	23.79%	-75.04%
Operating Profit	-$1.079M	-$1.112M	-$4.152M
YoY Change	35.26%	30.43%	-52.06%
Interest Expense	-$387.4K	-$117.3K	$21.33K
YoY Change	-1090.13%	-261.83%	-96.4%
% of Operating Profit
Other Income/Expense, Net	-$460.9K	$0.00	$537.8K
YoY Change	141.44%		-2456.01%
Pretax Income	-$1.540M	-$1.286M	-$3.614M
YoY Change	55.76%	-63.53%	-55.2%
Income Tax
% Of Pretax Income
Net Earnings	-$1.540M	-$1.286M	-$1.012M
YoY Change	53.51%	-70.53%	-88.52%
Net Earnings / Revenue	-193.75%	-138.07%	-17.69%
Basic Earnings Per Share	-$0.01		$0.00
Diluted Earnings Per Share	-$0.01	$0.00	$0.00
COMMON SHARES
Basic Shares Outstanding	281.1M shares	267.4M shares	262.9M shares
Diluted Shares Outstanding	281.8M shares		262.9M shares

Balance Sheet

Concept	2024 Q2	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$172.7K	$247.2K	$247.2K
YoY Change	-81.21%	299.45%	299.45%
Cash & Equivalents	$172.7K	$247.2K
Short-Term Investments
Other Short-Term Assets	$84.79K	$50.10K	$50.10K
YoY Change	-100.0%	-96.76%	-96.76%
Inventory	$96.43K	$133.2K	$133.2K
Prepaid Expenses
Receivables	$38.56K	$20.86K	$25.97K
Other Receivables	$1.663M	$199.7K	$199.7K
Total Short-Term Assets	$2.006M	$656.2K	$656.2K
YoY Change	11.92%	-69.4%	-69.4%
LONG-TERM ASSETS
Property, Plant & Equipment	$234.4K	$290.8K	$1.227M
YoY Change	-33.2%	-29.62%	28.67%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$50.05K	$50.05K	$50.05K
YoY Change	-97.05%	-1.69%	-1.69%
Total Long-Term Assets	$1.854M	$3.624M	$3.624M
YoY Change	-50.33%	48.76%	48.76%
TOTAL ASSETS
Total Short-Term Assets	$2.006M	$656.2K	$656.2K
Total Long-Term Assets	$1.854M	$3.624M	$3.624M
Total Assets	$3.860M	$4.280M	$4.280M
YoY Change	-30.14%	-6.56%	-6.56%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$794.4K	$612.0K	$612.0K
YoY Change	-46.06%	-61.81%	-61.81%
Accrued Expenses	$73.01K	$91.24K	$326.0K
YoY Change	-66.84%	-73.51%	-5.35%
Deferred Revenue	$284.2K	$271.8K
YoY Change	-30.76%	-52.72%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$342.7K	$584.3K	$584.3K
YoY Change	-14.23%	81.66%	81.66%
Total Short-Term Liabilities	$3.396M	$2.412M	$2.412M
YoY Change	2.31%	-30.58%	-30.58%
LONG-TERM LIABILITIES
Long-Term Debt	$450.0K	$450.0K	$450.0K
YoY Change	-6.25%	900.0%	-9.09%
Other Long-Term Liabilities	$438.6K	$613.4K	$613.4K
YoY Change	184.3%	106.83%	106.83%
Total Long-Term Liabilities	$888.6K	$1.063M	$1.063M
YoY Change	40.09%	2263.09%	34.34%
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.396M	$2.412M	$2.412M
Total Long-Term Liabilities	$888.6K	$1.063M	$1.063M
Total Liabilities	$4.284M	$3.475M	$3.475M
YoY Change	8.37%	-18.54%	-18.54%
SHAREHOLDERS EQUITY
Retained Earnings	-$44.96M	-$42.03M
YoY Change	10.82%	2.47%
Common Stock	$28.20K	$27.60K
YoY Change	6.46%	7.83%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$424.6K	$804.7K	$804.7K
YoY Change
Total Liabilities & Shareholders Equity	$3.860M	$4.280M	$4.280M
YoY Change	-30.14%	-6.56%	-6.56%

Cashflow Statement

Concept	2024 Q2	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$1.540M	-$1.286M	-$1.012M
YoY Change	53.51%	-70.53%	-88.52%
Depreciation, Depletion And Amortization	$29.53K	$88.27K	$352.0K
YoY Change	-66.55%	-57.39%	-57.56%
Cash From Operating Activities	-$858.7K	-$1.192M	-$4.145M
YoY Change	42.23%	98.59%	-5.0%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$1.500K	$1.500K
YoY Change			-93.63%
Acquisitions
YoY Change
Other Investing Activities		$1.188M	$3.508M
YoY Change			-773.0%
Cash From Investing Activities	$0.00	$1.186M	$3.506M
YoY Change	-100.0%		-743.62%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$850.0K
YoY Change			-11.16%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	1.008M	202.0K	$824.1K
YoY Change	267.78%	-59.94%	-50.89%
NET CHANGE
Cash From Operating Activities	-858.7K	-1.192M	-$4.145M
Cash From Investing Activities	0.000	1.186M	$3.506M
Cash From Financing Activities	1.008M	202.0K	$824.1K
Net Change In Cash	149.2K	195.9K	$185.3K
YoY Change	-82.45%	-303.48%	-105.74%
FREE CASH FLOW
Cash From Operating Activities	-$858.7K	-$1.192M	-$4.145M
Capital Expenditures	$0.00	$1.500K	$1.500K
Free Cash Flow	-$858.7K	-$1.194M	-$4.146M
YoY Change		98.84%	-5.48%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2022	hlyk	Gain From Realization Of Contingent Sale Consideration Receivable GainFromRealizationOfContingentSaleConsiderationReceivable		usd
CY2023	us-gaap	Income Taxes Paid IncomeTaxesPaid		usd
CY2022Q4	hlyk	Accrued Warrant Liability Current AccruedWarrantLiabilityCurrent	92641	usd
CY2023Q4	us-gaap	Goodwill Goodwill		usd
CY2022Q4	hlyk	Contingent Sale Consideration Receivable Long Term Portion ContingentSaleConsiderationReceivableLongTermPortion		usd
CY2022Q4	hlyk	Indemnification Liability IndemnificationLiability		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Entity File Number EntityFileNumber	000-55768
CY2023	dei	Entity Registrant Name EntityRegistrantName	HealthLynked Corp.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	47-1634127
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	1265 Creekside Parkway
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 302
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Naples
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	34108
CY2023	dei	City Area Code CityAreaCode	(800)
CY2023	dei	Local Phone Number LocalPhoneNumber	928-7144
CY2023	dei	Security12b Title Security12bTitle	Common Stock, par value $0.0001 per share
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	12005039	usd
CY2024Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	281064958	shares
CY2023	dei	Auditor Name AuditorName	RBSM LLP
CY2023	dei	Auditor Location AuditorLocation	New York, NY
CY2023	dei	Auditor Firm AuditorFirmId	587
CY2023Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	247222	usd
CY2022Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	61891	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	20861	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	72284	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	133222	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	192833	usd
CY2023Q4	us-gaap	Contract With Customer Asset Gross Current ContractWithCustomerAssetGrossCurrent	5110	usd
CY2022Q4	us-gaap	Contract With Customer Asset Gross Current ContractWithCustomerAssetGrossCurrent	269736	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	50100	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	92940	usd
CY2023Q4	hlyk	Contingent Sale Consideration Receivable Current Portion ContingentSaleConsiderationReceivableCurrentPortion	199645	usd
CY2022Q4	us-gaap	Assets Held For Sale Not Part Of Disposal Group Current AssetsHeldForSaleNotPartOfDisposalGroupCurrent	1454856	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	656160	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	2144540	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	521062	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	397194	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	290755	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	413123	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	258690	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	30531	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	883848	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1112007	usd
CY2022Q4	us-gaap	Goodwill Goodwill	319958	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	935812	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	540181	usd
CY2023Q4	hlyk	Deferred Equity Compensation And Deposit DeferredEquityCompensationAndDeposit	50047	usd
CY2022Q4	hlyk	Deferred Equity Compensation And Deposit DeferredEquityCompensationAndDeposit	50907	usd
CY2023Q4	hlyk	Contingent Sale Consideration Receivable Long Term Portion ContingentSaleConsiderationReceivableLongTermPortion	1463518	usd
CY2023Q4	us-gaap	Assets Assets	4280140	usd
CY2022Q4	us-gaap	Assets Assets	4580716	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	611989	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1602558	usd
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	271774	usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	574847	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	326033	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	344464	usd
CY2023Q4	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	166487	usd
CY2022Q4	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	37748	usd
CY2023Q4	us-gaap	Other Notes Payable Current OtherNotesPayableCurrent	584323	usd
CY2022Q4	us-gaap	Other Notes Payable Current OtherNotesPayableCurrent	291650	usd
CY2023Q4	hlyk	Indemnification Liability IndemnificationLiability	143974	usd
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	2189	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	130068	usd
CY2022Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	25000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2412024	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3474697	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	613386	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	198330	usd
CY2023Q4	hlyk	Government And Vendor Notes Payable Long Term Portion GovernmentAndVendorNotesPayableLongTermPortion	450000	usd
CY2022Q4	hlyk	Government And Vendor Notes Payable Long Term Portion GovernmentAndVendorNotesPayableLongTermPortion	450000	usd
CY2022Q4	us-gaap	Other Long Term Debt Noncurrent OtherLongTermDebtNoncurrent	143239	usd
CY2023Q4	us-gaap	Liabilities Liabilities	3475410	usd
CY2022Q4	us-gaap	Liabilities Liabilities	4266266	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	275964958	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	275964958	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	255940389	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	255940389	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	27597	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	25594	usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	2750	usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	2750	usd
CY2023Q4	hlyk	Common Stock Issuable Par Value CommonStockIssuableParValue	0.0001
CY2022Q4	hlyk	Common Stock Issuable Par Value CommonStockIssuableParValue	0.0001
CY2023Q4	hlyk	Common Stock Issuable Shares CommonStockIssuableShares	2764352	shares
CY2022Q4	hlyk	Common Stock Issuable Shares CommonStockIssuableShares	2585542	shares
CY2023Q4	hlyk	Common Stock Issuable Value CommonStockIssuableValue	281682	usd
CY2022Q4	hlyk	Common Stock Issuable Value CommonStockIssuableValue	225584	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	42525837	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	41081455	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-42033136	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-41020933	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	804730	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	314450	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	4280140	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	4580716	usd
CY2023	us-gaap	Revenues Revenues	5722379	usd
CY2022	us-gaap	Revenues Revenues	5858202	usd
CY2023	us-gaap	Labor And Related Expense LaborAndRelatedExpense	3231117	usd
CY2022	us-gaap	Labor And Related Expense LaborAndRelatedExpense	3335695	usd
CY2023	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	2205085	usd
CY2022	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	2566191	usd
CY2023	hlyk	Cost Of Product Revenue CostOfProductRevenue	142501	usd
CY2022	hlyk	Cost Of Product Revenue CostOfProductRevenue	463156	usd
CY2023	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	3623402	usd
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	4577490	usd
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	352027	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	829481	usd
CY2023	us-gaap	Other Asset Impairment Charges OtherAssetImpairmentCharges	319958	usd
CY2022	us-gaap	Other Asset Impairment Charges OtherAssetImpairmentCharges	2745563	usd
CY2023	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	9874090	usd
CY2022	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	14517576	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-4151711	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-8659374	usd
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-145212	usd
CY2023	hlyk	Gain From Expiration Of Liability Classified Equity Instruments GainFromExpirationOfLiabilityClassifiedEquityInstruments	92641	usd
CY2022	us-gaap	Financing Interest Expense FinancingInterestExpense	110000	usd
CY2023	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	427808	usd
CY2022	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	55282	usd
CY2023	hlyk	Gain From Realization Of Contingent Sale Consideration Receivable GainFromRealizationOfContingentSaleConsiderationReceivable	1090857	usd
CY2023	hlyk	Gain Loss On Change In Fair Value Of Contingent Acquisition Consideration GainLossOnChangeInFairValueOfContingentAcquisitionConsideration	-11094	usd
CY2022	hlyk	Gain Loss On Change In Fair Value Of Contingent Acquisition Consideration GainLossOnChangeInFairValueOfContingentAcquisitionConsideration	-779999	usd
CY2023	us-gaap	Interest Expense Other InterestExpenseOther	83812	usd
CY2022	us-gaap	Interest Expense Other InterestExpenseOther	22825	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	537760	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	591892	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3613951	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-8067482	usd
CY2023	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-3613951	usd
CY2022	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-8067482	usd
CY2023	hlyk	Loss From Operations Of Discontinued Operations LossFromOperationsOfDiscontinuedOperations	72321	usd
CY2022	hlyk	Loss From Operations Of Discontinued Operations LossFromOperationsOfDiscontinuedOperations	748262	usd
CY2023	hlyk	Gain From Disposal Of Discontinued Operations GainFromDisposalOfDiscontinuedOperations	2674069	usd
CY2023	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	2601748	usd
CY2022	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-748262	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-1012203	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-8815744	usd
CY2022	hlyk	Deemed Dividend Amortization Of Beneficial Conversion Feature DeemedDividendAmortizationOfBeneficialConversionFeature	353571	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1012203	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-9169315	usd
CY2023	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.01
CY2022	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.03
CY2023	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.01
CY2022	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.03
CY2023	us-gaap	Discontinued Operation Gain Loss On Disposal Of Discontinued Operation Net Of Tax Per Basic Share DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTaxPerBasicShare	0.01
CY2022	us-gaap	Discontinued Operation Gain Loss On Disposal Of Discontinued Operation Net Of Tax Per Basic Share DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTaxPerBasicShare	0
CY2023	us-gaap	Discontinued Operation Gain Loss On Disposal Of Discontinued Operation Net Of Tax Per Diluted Share DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTaxPerDilutedShare	0.01
CY2022	us-gaap	Discontinued Operation Gain Loss On Disposal Of Discontinued Operation Net Of Tax Per Diluted Share DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTaxPerDilutedShare	0
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.04
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.04
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	262891873	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	243419736	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	262891873	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	243419736	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	7203894	usd
CY2022	hlyk	Sales Of Common Stock Value Pursuant To Standby Equity Purchase Agreement SalesOfCommonStockValuePursuantToStandbyEquityPurchaseAgreement	451203	usd
CY2022	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	100000	usd
CY2022	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	570349	usd
CY2022	us-gaap	Stock And Warrants Issued During Period Value Preferred Stock And Warrants StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants	214651	usd
CY2022	hlyk	Fair Value Of Warrants Allocated To Proceeds Of Related Party Debt FairValueOfWarrantsAllocatedToProceedsOfRelatedPartyDebt	35281	usd
CY2022	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	103804	usd
CY2022	hlyk	Consultant Fees Payable With Common Shares And Warrants ConsultantFeesPayableWithCommonSharesAndWarrants	321301	usd
CY2022	us-gaap	Stock Issued During Period Value Employee Stock Ownership Plan StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan	129711	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-8815744	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	314450	usd
CY2023	hlyk	Sales Of Common Stock Value Pursuant To Standby Equity Purchase Agreement SalesOfCommonStockValuePursuantToStandbyEquityPurchaseAgreement	18765	usd
CY2023	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	546183	usd
CY2023	us-gaap	Stock And Warrants Issued During Period Value Preferred Stock And Warrants StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants	303817	usd
CY2023	hlyk	Fair Value Of Warrants Allocated To Proceeds Of Related Party Debt FairValueOfWarrantsAllocatedToProceedsOfRelatedPartyDebt	221899	usd
CY2023	hlyk	Fair Value Of Warrants Allocated To Proceeds Of Third Party Debt FairValueOfWarrantsAllocatedToProceedsOfThirdPartyDebt	15140	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature	33000	usd
CY2023	hlyk	Fair Value Of Warrants Issued To Pay Liability FairValueOfWarrantsIssuedToPayLiability	10820	usd
CY2023	hlyk	Consultant Fees Payable With Common Shares And Warrants ConsultantFeesPayableWithCommonSharesAndWarrants	180698	usd
CY2023	us-gaap	Stock Issued During Period Value Employee Stock Ownership Plan StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan	118923	usd
CY2023	hlyk	Incremental Fair Value Of Repriced Warrants IncrementalFairValueOfRepricedWarrants	4358	usd
CY2023	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	48880	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-1012203	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	804730	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-1012203	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-8815744	usd
CY2023	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Before Income Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax	-72321	usd
CY2022	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Before Income Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax	-748262	usd
CY2023	hlyk	Gain From Disposal Of Discontinued Operation GainFromDisposalOfDiscontinuedOperation	-2674069	usd
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	352027	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	829481	usd
CY2023	us-gaap	Asset Impairment Charges AssetImpairmentCharges	319958	usd
CY2022	us-gaap	Asset Impairment Charges AssetImpairmentCharges	2745563	usd
CY2023	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	303979	usd
CY2022	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	439763	usd
CY2023	hlyk	Gain From Expiration Of Liability Classified Equity Instruments GainFromExpirationOfLiabilityClassifiedEquityInstruments	92641	usd
CY2023	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	427808	usd
CY2022	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	55282	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	100000	usd
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-145212	usd
CY2023	hlyk	Gain From Realization Of Contingent Sale Consideration Receivable GainFromRealizationOfContingentSaleConsiderationReceivable	1090857	usd
CY2023	hlyk	Gain Loss On Change In Fair Value Of Contingent Acquisition Consideration GainLossOnChangeInFairValueOfContingentAcquisitionConsideration	-11094	usd
CY2022	hlyk	Gain Loss On Change In Fair Value Of Contingent Acquisition Consideration GainLossOnChangeInFairValueOfContingentAcquisitionConsideration	-779999	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-28916	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-36510	usd
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-59611	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	44631	usd
CY2023	us-gaap	Increase Decrease In Contract With Customer Asset IncreaseDecreaseInContractWithCustomerAsset	-264626	usd
CY2022	us-gaap	Increase Decrease In Contract With Customer Asset IncreaseDecreaseInContractWithCustomerAsset	269736	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	31299	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-51532	usd
CY2023	hlyk	Increase Decrease In Right Of Use Lease Assets IncreaseDecreaseInRightOfUseLeaseAssets	403287	usd
CY2022	hlyk	Increase Decrease In Right Of Use Lease Assets IncreaseDecreaseInRightOfUseLeaseAssets	351718	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-780239	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	701605	usd
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-402292	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-350566	usd
CY2023	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-303073	usd
CY2022	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	527010	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-4020022	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-3673950	usd
CY2023	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	-124846	usd
CY2022	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	-689070	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4144868	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4363020	usd
CY2022	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	313802	usd
CY2022	us-gaap	Payment For Contingent Consideration Liability Investing Activities PaymentForContingentConsiderationLiabilityInvestingActivities	207384	usd
CY2023	hlyk	Proceeds From Sale Of Discontinued Operations ProceedsFromSaleOfDiscontinuedOperations	3507612	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1500	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	23564	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	3506112	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-544750	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	3506112	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-544750	usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	850000	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	956787	usd
CY2023	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	1198500	usd
CY2022	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	260000	usd
CY2023	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	1283249	usd
CY2022	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	683300	usd
CY2023	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	1411004	usd
CY2022	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	28000	usd
CY2023	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	1096658	usd
CY2022	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	194072	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	824087	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	1678015	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	824087	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1678015	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	185331	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-3229755	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	61891	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3291646	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	247222	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	61891	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	21041	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	5923	usd
CY2023	hlyk	Common Stock To Be Issued Now Issued CommonStockToBeIssuedNowIssued	108928	usd
CY2022	hlyk	Common Stock To Be Issued Now Issued CommonStockToBeIssuedNowIssued	305069	usd
CY2023	hlyk	Net Carrying Value Of Equity Liabilitiesassets Written Off NetCarryingValueOfEquityLiabilitiesassetsWrittenOff	64647	usd
CY2022	hlyk	Net Carrying Value Of Equity Liabilitiesassets Written Off NetCarryingValueOfEquityLiabilitiesassetsWrittenOff	428859	usd
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	798918	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	284905	usd
CY2023	hlyk	Proceeds From Sale Of Common Stock Under Standby Equity Purchase Agreement Applied To Note ProceedsFromSaleOfCommonStockUnderStandbyEquityPurchaseAgreementAppliedToNote	18765	usd
CY2022	hlyk	Proceeds From Sale Of Common Stock Under Standby Equity Purchase Agreement Applied To Note ProceedsFromSaleOfCommonStockUnderStandbyEquityPurchaseAgreementAppliedToNote	279415	usd
CY2023	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	367919	usd
CY2022	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	153631	usd
CY2023	hlyk	Fair Value Of Warrants Allocated To Proceeds Of Notes Payable FairValueOfWarrantsAllocatedToProceedsOfNotesPayable	187013	usd
CY2022	hlyk	Fair Value Of Warrants Allocated To Proceeds Of Notes Payable FairValueOfWarrantsAllocatedToProceedsOfNotesPayable	35281	usd
CY2023	hlyk	Fair Value Of Beneficial Conversion Feature Allocated To Proceeds Of Notes Payable FairValueOfBeneficialConversionFeatureAllocatedToProceedsOfNotesPayable	33000	usd
CY2023	hlyk	Fair Value Of Warrants Issued To Extend Debt FairValueOfWarrantsIssuedToExtendDebt	50025	usd
CY2023	hlyk	Warrant Liability Incurred In Connection With Collection Of Contingent Sale Consideration Receivable WarrantLiabilityIncurredInConnectionWithCollectionOfContingentSaleConsiderationReceivable	10820	usd
CY2023	hlyk	Fair Value Of Shares Issued To Pay Vendor Accounts Payable Balance FairValueOfSharesIssuedToPayVendorAccountsPayableBalance	48881	usd
CY2022	hlyk	Fair Value Of Shares Issued As Purchase Price Consideration FairValueOfSharesIssuedAsPurchasePriceConsideration	103804	usd
CY2014Q3	hlyk	Number Of Authorized Shares NumberOfAuthorizedShares	250000000	shares
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Use of Estimates</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect certain reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. Accordingly, actual results could differ from those estimates. Significant estimates include assumptions about fair valuation of acquired intangible assets; cash flow and fair value assumptions associated with measurements of contingent sale consideration receivable, contingent acquisition consideration payable, and impairment of intangible assets and goodwill; valuation of inventory; collection of accounts receivable; the valuation and recognition of stock-based compensation expense; valuation allowance for deferred tax assets; and borrowing rate consideration for right-of-use (“ROU”) lease assets including related lease liability and useful life of fixed assets.</p>
CY2023Q4	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
CY2023Q4	hlyk	Cash Balances In Excess Of Fdic Insured Limit CashBalancesInExcessOfFDICInsuredLimit	0	usd
CY2022Q4	hlyk	Cash Balances In Excess Of Fdic Insured Limit CashBalancesInExcessOfFDICInsuredLimit	0	usd
CY2023	hlyk	Percentage Of Customers Accounts Receivable Billings PercentageOfCustomersAccountsReceivableBillings	0.58	pure
CY2023Q4	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	34481	usd
CY2022Q4	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	98180	usd
CY2023Q4	us-gaap	Accounts Notes And Loans Receivable Net Current AccountsNotesAndLoansReceivableNetCurrent	20861	usd
CY2022Q4	us-gaap	Accounts Notes And Loans Receivable Net Current AccountsNotesAndLoansReceivableNetCurrent	49777	usd
CY2023Q4	hlyk	Consulting Accounts Receivable ConsultingAccountsReceivable	0	usd
CY2022Q4	hlyk	Consulting Accounts Receivable ConsultingAccountsReceivable	22506	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	usd
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Concentrations of Credit Risk</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company’s financial instruments that are exposed to a concentration of credit risk are cash and accounts receivable. There are no patients/customers that represent 10% or more of the Company’s revenue or accounts receivable. Generally, the Company’s cash and cash equivalents are in checking accounts. The Company relies on a sole supplier for the fulfillment of substantially all of its product sales made through MOD.</p>
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1484488	shares
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1651435	shares
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	247222	usd
CY2023	hlyk	Working Capital Deficit WorkingCapitalDeficit	1755864	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-1012203	usd
CY2023	hlyk	Gain From Realization Of Contingent Sale Consideration Receivable GainFromRealizationOfContingentSaleConsiderationReceivable	1090857	usd
CY2023	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-3613951	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4144868	usd
CY2023	us-gaap	Proceeds From Divestiture Of Businesses ProceedsFromDivestitureOfBusinesses	500000	usd
CY2023Q4	us-gaap	Other Notes Payable OtherNotesPayable	2507662	usd
CY2023	hlyk	Proceeds From The Sale Of Common Stock ProceedsFromTheSaleOfCommonStock	850000	usd
CY2022Q3	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	30000000	shares
CY2023Q4	us-gaap	Cash Including Discontinued Operations CashIncludingDiscontinuedOperations	750000	usd
CY2023	us-gaap	Discontinued Operation Amount Of Adjustment To Prior Period Gain Loss On Disposal Before Income Tax DiscontinuedOperationAmountOfAdjustmentToPriorPeriodGainLossOnDisposalBeforeIncomeTax	1750000	usd
CY2023Q4	us-gaap	Other Receivables Gross Current OtherReceivablesGrossCurrent	1873993	usd
CY2023	us-gaap	Proceeds From Commissions Received ProceedsFromCommissionsReceived	1186231	usd
CY2023Q4	us-gaap	Disposal Group Including Discontinued Operation Consideration DisposalGroupIncludingDiscontinuedOperationConsideration	500000	usd
CY2023Q1	hlyk	Stub Period Reimbursement StubPeriodReimbursement	31381	usd
CY2023	hlyk	Aggregate Merger Consideration Percentage AggregateMergerConsiderationPercentage	0.01	pure
CY2023	us-gaap	Asset Acquisition Consideration Transferred Other Assets AssetAcquisitionConsiderationTransferredOtherAssets	3000000	usd
CY2022Q4	us-gaap	Disposal Group Including Discontinued Operation Intangible Assets Current DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent	1073000	usd
CY2022Q4	us-gaap	Disposal Group Including Discontinued Operation Goodwill Current DisposalGroupIncludingDiscontinuedOperationGoodwillCurrent	381856	usd
CY2022Q4	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent	1454856	usd
CY2022Q4	us-gaap	Disposal Group Including Discontinued Operation Other Current Liabilities DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities	25000	usd
CY2022Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation	25000	usd
CY2023	us-gaap	Disposal Group Including Discontinued Operation Other Expense DisposalGroupIncludingDiscontinuedOperationOtherExpense	95967	usd
CY2022	us-gaap	Disposal Group Including Discontinued Operation Other Expense DisposalGroupIncludingDiscontinuedOperationOtherExpense	1088127	usd
CY2023	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Before Income Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax	-72321	usd
CY2022	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Before Income Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax	-748262	usd
CY2023	us-gaap	Discontinued Operation Gain Loss From Disposal Of Discontinued Operation Before Income Tax DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax	-72321	usd
CY2022	us-gaap	Discontinued Operation Gain Loss From Disposal Of Discontinued Operation Before Income Tax DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax	-748262	usd
CY2023	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	-124846	usd
CY2022	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	-689070	usd
CY2023	hlyk	Cash Consideration Paid At Signing CashConsiderationPaidAtSigning	750000	usd
CY2023	hlyk	Incremental Cash Consideration IncrementalCashConsideration	1311567	usd
CY2023	hlyk	Initial Public Offering Share Consideration InitialPublicOfferingShareConsideration	1463517	usd
CY2023	hlyk	Two Zero Two Two Mssp Consideration TwoZeroTwoTwoMSSPConsideration	312987	usd
CY2023	hlyk	Physician Advance Consideration PhysicianAdvanceConsideration	199645	usd
CY2023	hlyk	Stub Period Reimbursement StubPeriodReimbursement	31381	usd
CY2023	hlyk	Fair Value Of Contingent Consideration Receivable FairValueOfContingentConsiderationReceivable	3319097	usd
CY2023	hlyk	Fair Value Of Consideration Received And Receivable FairValueOfConsiderationReceivedAndReceivable	4069097	usd
CY2023Q4	us-gaap	Disposal Group Including Discontinued Operation Prepaid And Other Assets DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets	1500	usd
CY2023Q4	us-gaap	Disposal Group Including Discontinued Operation Intangible Assets DisposalGroupIncludingDiscontinuedOperationIntangibleAssets	1073000	usd
CY2023Q4	us-gaap	Disposal Group Including Discontinued Operation Goodwill1 DisposalGroupIncludingDiscontinuedOperationGoodwill1	381856	usd
CY2023Q4	us-gaap	Disposal Group Including Discontinued Operation Other Liabilities DisposalGroupIncludingDiscontinuedOperationOtherLiabilities	20278	usd
CY2023Q4	hlyk	Disposal Group Contingent Acquisition Consideration DisposalGroupContingentAcquisitionConsideration	185024	usd
CY2023Q4	hlyk	Discontinued Operation Amounts Of Net Book Value Of Assets And Liabilities Sold DiscontinuedOperationAmountsOfNetBookValueOfAssetsAndLiabilitiesSold	1251054	usd
CY2023	us-gaap	Discontinued Operation Tax Effect Of Income Loss From Disposal Of Discontinued Operation DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation	2674069	usd
CY2023	hlyk	Fair Value Of Consideration Received And Receivable FairValueOfConsiderationReceivedAndReceivable	4069097	usd
CY2023Q4	us-gaap	Sale Leaseback Transaction Net Book Value SaleLeasebackTransactionNetBookValue	1251054	usd
CY2023Q4	hlyk	Indemnification Liability IndemnificationLiability	143974	usd
CY2023	hlyk	Gain From Disposal Of Discontinued Operations GainFromDisposalOfDiscontinuedOperations	2674069	usd
CY2023Q4	us-gaap	Other Receivables OtherReceivables	750000	usd
CY2023	hlyk	Stub Period Reimbursement StubPeriodReimbursement	31381	usd
CY2023	hlyk	Resolved Net Settlement Amount ResolvedNetSettlementAmount	3496792	usd
CY2023	hlyk	Estimated Fair Value On Sale EstimatedFairValueOnSale	-2405935	usd
CY2023	us-gaap	Gain Loss On Condemnation GainLossOnCondemnation	1090857	usd
CY2023	us-gaap	Sale Of Stock Consideration Received Per Transaction SaleOfStockConsiderationReceivedPerTransaction	1463518	usd
CY2023	hlyk	Physician Advance Consideration PhysicianAdvanceConsideration	199645	usd
CY2023Q4	hlyk	Contingent Sales Consideration Receivable Long Term Portion ContingentSalesConsiderationReceivableLongTermPortion	1663163	usd
CY2023	hlyk	Terms Of Acquisitions Description TermsOfAcquisitionsDescription	Under the terms of acquisition, the Company paid AEU equity holders consideration of (i) $139,923 cash (less $11,198 cash on hand at AEU as of the closing date), (ii) payment in cash of direct financial obligation of AEU on, or in close proximity to, the date of the business combination, in the amount of $185,077, and (iii) 792,394 shares of Company common stock at closing with a fair value of $103,804 determined using the average closing price of the Company’s common shares for the five days preceding the acquisition date. The total consideration fair value represents a transaction value of $417,606.
CY2023	hlyk	Payments To Fair Value Of Shares Issued PaymentsToFairValueOfSharesIssued	103804	usd
CY2023	hlyk	Payments To Acquire Businesses Net Cash Acquired Cash Consideration PaymentsToAcquireBusinessesNetCashAcquiredCashConsideration	139923	usd
CY2023	hlyk	Payment Of Aeu Debt Obligations In Cash PaymentOfAEUDebtObligationsInCash	185077	usd
CY2023	hlyk	Less Cash Received LessCashReceived	11198	usd
CY2023	hlyk	Acquisition Of Fair Value Total Consideration AcquisitionOfFairValueTotalConsideration	417606	usd
CY2023Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Inventory BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory	13272	usd
CY2023Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Noncurrent Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets	152759	usd
CY2023Q4	hlyk	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Right Of Use Asset Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssetAssets	80264	usd
CY2023Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Accounts Payable BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable	33037	usd
CY2023Q4	us-gaap	Loans Payable To Bank LoansPayableToBank	35346	usd
CY2023Q4	hlyk	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Lease Liability BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLeaseLiability	80264	usd
CY2023Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Net BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet	97648	usd
CY2023Q4	us-gaap	Goodwill Gross GoodwillGross	319958	usd
CY2022	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	6127394	usd
CY2022	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	-5930867	usd
CY2023Q4	us-gaap	Prepaid Insurance PrepaidInsurance	11209	usd
CY2022Q4	us-gaap	Prepaid Insurance PrepaidInsurance	17733	usd
CY2023Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	38391	usd
CY2022Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	6989	usd
CY2023Q4	us-gaap	Prepaid Rent PrepaidRent	50547	usd
CY2022Q4	us-gaap	Prepaid Rent PrepaidRent	44125	usd
CY2022Q4	hlyk	Deferred Equity Compensation Current DeferredEquityCompensationCurrent	75000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	100147	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	143847	usd
CY2023Q4	hlyk	Deferred Equity Compensation And Deposit DeferredEquityCompensationAndDeposit	50047	usd
CY2022Q4	hlyk	Deferred Equity Compensation And Deposit DeferredEquityCompensationAndDeposit	50907	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	50100	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	92940	usd
CY2023	hlyk	Fair Value Of Equity Compensation FairValueOfEquityCompensation	0	usd
CY2022	hlyk	Fair Value Of Equity Compensation FairValueOfEquityCompensation	90000	usd
CY2023	us-gaap	Adjustment For Amortization AdjustmentForAmortization	10353	usd
CY2022	us-gaap	Adjustment For Amortization AdjustmentForAmortization	46771	usd
CY2023	hlyk	Unearned Amounts Written Off UnearnedAmountsWrittenOff	64647	usd
CY2022	hlyk	Unearned Amounts Written Off UnearnedAmountsWrittenOff	13338	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	811817	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	810317	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	521062	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	397194	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	290755	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	413123	usd
CY2023	us-gaap	Depreciation Depreciation	123868	usd
CY2022	us-gaap	Depreciation Depreciation	113681	usd
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	228159	usd
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	715800	usd
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y7M6D
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.1533	pure
CY2023Q4	us-gaap	Interest Payable Current InterestPayableCurrent	57074	usd
CY2022Q4	us-gaap	Interest Payable Current InterestPayableCurrent	63615	usd
CY2023Q4	hlyk	Product Return Allowance1 ProductReturnAllowance1	2095	usd
CY2022Q4	hlyk	Product Return Allowance1 ProductReturnAllowance1	2352	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	935812	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	540181	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	326033	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	344464	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	613386	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	198330	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	939419	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	542794	usd
CY2023	us-gaap	Operating Lease Expense OperatingLeaseExpense	468901	usd
CY2022	us-gaap	Operating Lease Expense OperatingLeaseExpense	430719	usd
CY2023Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	251479	usd
CY2022Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	863662	usd
CY2023Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	110103	usd
CY2022Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	190633	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	91238	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	389655	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	611989	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1602558	usd
	us-gaap	Gross Profit GrossProfit	1873993	usd
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	1186231	usd
CY2023Q4	us-gaap	Accrued Fees And Other Revenue Receivable AccruedFeesAndOtherRevenueReceivable	100000	usd
CY2023Q4	us-gaap	Contract With Customer Asset Gross Current ContractWithCustomerAssetGrossCurrent	5110	usd
CY2022Q4	us-gaap	Contract With Customer Asset Gross Current ContractWithCustomerAssetGrossCurrent	269736	usd
CY2023Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	271774	usd
CY2022Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	574847	usd
CY2023Q1	us-gaap	Investment Interest Rate InvestmentInterestRate	0.15	pure
CY2023Q4	us-gaap	Investment Maturity Date InvestmentMaturityDate	2024-02-28
CY2023Q4	us-gaap	Interest Receivable InterestReceivable	7456	usd
CY2022Q4	us-gaap	Interest Receivable InterestReceivable	0	usd
CY2023	us-gaap	Interest Expense InterestExpense	21331	usd
CY2022	us-gaap	Interest Expense InterestExpense	0	usd
CY2023Q4	hlyk	Plus Deferred Compensation Payable To Related Party PlusDeferredCompensationPayableToRelatedParty	300600	usd
CY2022Q4	hlyk	Plus Deferred Compensation Payable To Related Party PlusDeferredCompensationPayableToRelatedParty	300600	usd
CY2023	us-gaap	Deferred Compensation Arrangement With Individual Compensation Expense DeferredCompensationArrangementWithIndividualCompensationExpense	20000	usd
CY2023	hlyk	Compensation Arrangements CompensationArrangements	408164	usd
CY2022	hlyk	Compensation Arrangements CompensationArrangements	402144	usd
CY2023	hlyk	Consulting Fees ConsultingFees	139423	usd
CY2022	hlyk	Consulting Fees ConsultingFees	128269	usd
CY2023Q4	us-gaap	Loans Receivable With Fixed Rates Of Interest1 LoansReceivableWithFixedRatesOfInterest1	7533	usd
CY2022Q4	us-gaap	Loans Receivable With Fixed Rates Of Interest1 LoansReceivableWithFixedRatesOfInterest1	16902	usd
CY2023	us-gaap	Interest Income Other InterestIncomeOther	21530	usd
CY2023	us-gaap	Principal Transactions Revenue PrincipalTransactionsRevenue	450000	usd
CY2022	us-gaap	Principal Transactions Revenue PrincipalTransactionsRevenue	450000	usd
CY2023Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	450000	usd
CY2022Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	450000	usd
CY2022	us-gaap	Payments For Rent PaymentsForRent	29057	usd
CY2022Q3	us-gaap	Financing Receivable Excluding Accrued Interest Nonaccrual Percent Past Due FinancingReceivableExcludingAccruedInterestNonaccrualPercentPastDue	0.05	pure
CY2022Q3	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	0.02	pure
CY2022Q4	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	224400	usd
CY2023Q4	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	189000	usd
CY2022Q3	hlyk	Aggregate Percentage AggregatePercentage	0.30	pure
CY2022Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent	0.96	pure
CY2022Q3	us-gaap	Derivative Underlying Investment Shares DerivativeUnderlyingInvestmentShares	30000000	shares
CY2023Q4	us-gaap	Cash Cash	10000	usd
CY2023Q4	us-gaap	Fair Value Concentration Of Risk Commitments FairValueConcentrationOfRiskCommitments	100000	usd
CY2022	us-gaap	Financing Interest Expense FinancingInterestExpense	110000	usd
CY2023	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	225000	shares
CY2022Q4	us-gaap	Shares Issued SharesIssued	664076	shares
CY2023	hlyk	Schedule Of Common Stock Issuable ScheduleOfCommonStockIssuable	As of December 31, 2023 and 2022, the Company was obligated to issue the following shares:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31, 2022</b></span></td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td><b> </b></td><td style="padding-bottom: 1.5pt"><b> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Amount</b></td><td style="padding-bottom: 1.5pt"><b> </b></td><td style="padding-bottom: 1.5pt"><b> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Shares</b></td><td style="padding-bottom: 1.5pt"><b> </b></td><td style="padding-bottom: 1.5pt"><b> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Amount</b></td><td style="padding-bottom: 1.5pt"><b> </b></td><td style="padding-bottom: 1.5pt"><b> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Shares</b></td><td style="padding-bottom: 1.5pt"><b> </b></td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left">Shares issuable to employees and consultants</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">261,682</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">2,356,188</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">210,584</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">2,183,398</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Shares issuable to independent directors</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">20,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">408,164</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">15,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">402,144</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">281,682</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">2,764,352</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">225,584</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">2,585,542</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table>
CY2023Q4	hlyk	Common Stock Issuables Value CommonStockIssuablesValue	281682	usd
CY2023Q4	hlyk	Common Stock Issuables Shares CommonStockIssuablesShares	2764352	shares
CY2022Q4	hlyk	Common Stock Issuables Value CommonStockIssuablesValue	225584	usd
CY2022Q4	hlyk	Common Stock Issuables Shares CommonStockIssuablesShares	2585542	shares
CY2023Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	18487860	shares
CY2022Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	9392101	shares
CY2023Q4	us-gaap	Derivative Net Liability Position Aggregate Fair Value DerivativeNetLiabilityPositionAggregateFairValue	794220	usd
CY2022Q4	us-gaap	Derivative Net Liability Position Aggregate Fair Value DerivativeNetLiabilityPositionAggregateFairValue	333162	usd
CY2023	hlyk	Pricing Model Utilized PricingModelUtilized	Binomial Lattice
CY2022	hlyk	Pricing Model Utilized PricingModelUtilized	Binomial Lattice
CY2022	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2	P5Y
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2023	hlyk	Share Based Compensation Arrangement By Share Based Payment Award Probability Of Exercise ShareBasedCompensationArrangementByShareBasedPaymentAwardProbabilityOfExercise	0.80	pure
CY2022	hlyk	Share Based Compensation Arrangement By Share Based Payment Award Probability Of Exercise ShareBasedCompensationArrangementByShareBasedPaymentAwardProbabilityOfExercise	0.80	pure
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	0.06
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	89270	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	12245	usd
CY2023	us-gaap	Net Amount At Risk By Product And Guarantee Weighted Average Period Remaining1 NetAmountAtRiskByProductAndGuaranteeWeightedAveragePeriodRemaining1	P1Y8M12D
CY2022	us-gaap	Stock Option Exercise Price Increase StockOptionExercisePriceIncrease	0.05
CY2022Q4	us-gaap	Additional Collateral Aggregate Fair Value AdditionalCollateralAggregateFairValue	174594	usd
CY2023	hlyk	Share Based Compensation Arrangement By Share Based Payment Award Forfeiture Rates ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeitureRates	0.20	pure
CY2022	hlyk	Share Based Compensation Arrangement By Share Based Payment Award Forfeiture Rates ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeitureRates	0.20	pure
CY2023Q4	us-gaap	Deferred Compensation Equity DeferredCompensationEquity	64647	usd
CY2022Q4	us-gaap	Deferred Compensation Equity DeferredCompensationEquity	13338	usd
CY2023	us-gaap	Loss Contingency Disclosures LossContingencyDisclosures	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 15 – CONTINGENT ACQUISITION CONSIDERATION</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Contingent acquisition consideration relates to future earn-out payments potentially payable related to the Company’s acquisitions of Hughes Center for Functional Medicine (“HCFM”) in 2019 and CHM and MOD in 2020. The terms of the earn-outs related to each acquisition require the Company to pay the former owners additional acquisition consideration for the achievement of prescribed revenue and/or earnings targets for performance of the underlying business for up to four years after the respective acquisition date. Contingent acquisition consideration for each entity is recorded at fair value using a probability-weighted discounted cash flow projection. The fair value of the contingent acquisition consideration is remeasured at the end of each reporting period and changes are included in the statement of operations under the caption “Change in fair value of contingent acquisition consideration.”</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Contingent acquisition consideration as of December 31, 2023 and 2022 was comprised of the following:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Fair value of CHM contingent acquisition consideration</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-159">---</div></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">185,024</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Fair value of MOD contingent acquisition consideration</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,189</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">13,283</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total contingent acquisition consideration</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,189</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">198,307</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less: long term portion</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-160">---</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(98,239</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt">Contingent acquisition consideration, current portion</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,189</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">100,068</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended December 31, 2023 and 2022, the Company recognized gains (losses) on the change in the fair value of contingent acquisition consideration as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">HCFM contingent acquisition consideration</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-161">---</div></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(35,260</td><td style="width: 1%; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">CHM contingent acquisition consideration</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-162">---</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">91,505</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">MOD contingent acquisition consideration</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">11,094</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">723,754</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt">Net gain on change in fair value of contingent acquisition consideration</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">11,094</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">779,999</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">All of the remaining $2,189 contingent acquisition consideration related to MOD matures in 2024 based on the performance of the business unit for the year ended December 31, 2024.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Hughes Center for Functional Medicine Acquisition – April 2019 </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 12, 2019, the Company acquired a 100% interest in HCFM, a medical practice engaged in improving the health of its patients through individualized and integrative health care. Under the terms of acquisition, the Company paid the seller $500,000 in cash, issued 3,968,254 shares of the Company’s common stock and agreed to an earn-out provision of $500,000 that may be earned based on the performance of NCFM in the years ended on the first, second and third anniversary dates of the acquisition closing. The total consideration fair value represented a transaction fair value of $1,764,672. In May 2020, the Company paid the seller $47,000 in satisfaction of the year 1 earn out. In May 2021, the Company paid the seller $196,000 in satisfaction of the year 2 earn out. In May 2022, the Company paid the seller $207,384 in satisfaction of the year 3 earn out. The Company has no further earn-out obligations related to the NCFM acquisition.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Cura Health Management LLC Acquisition – May 2020</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 18, 2020, the Company acquired a 100% interest in CHM and its wholly owned subsidiary AHP. The acquisition consideration included an earnout of up to $62,500, $125,000, $125,000 and $125,000 cash for years 1, 2, 3, and 4, respectively, based on achievement by the underlying business of revenue of at least $2,250,000 (50% weighting) and profit of at least $500,000 (50% weighting) in the year preceding each anniversary date of the closing (the “Future Earnout”). On January 17, 2023, the Company entered into the AHP Merger Agreement, pursuant to which the Buyer agreed to buy, and the Company agreed to sell, AHP.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">MedOffice Direct LLC Acquisition – October 2020 </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 19, 2020, the Company acquired a 100% interest in MOD, a virtual distributor of discounted medical supplies selling to both consumers and medical practices throughout the United States. Under the terms of acquisition, the Company paid the following consideration: (i) 19,045,563 shares of Company common stock issued at closing, (ii) partial satisfaction of certain outstanding debt obligations of MOD in the amount of $703,200 in cash paid by the Company, and (iii) up to 10,004,749 restricted shares of the Company’s common stock over a four-year period based on MOD achieving revenue targets in calendar years 2021, 2022, 2023, and 2024 of $1,500,000, $1,875,000, $2,344,000, and $2,930,000, respectively. The first, second and third years of earnout measured based on performance in calendar years 2021, 2022, and 2023, respectively, were not met. Because the MOD earnout is payable in a fixed number of shares for each earnout year, the fair value of MOD contingent acquisition consideration is dependent in large part on the price of the Company’s stock.</p>
CY2023Q4	us-gaap	Asset Acquisition Contingent Consideration Liability AssetAcquisitionContingentConsiderationLiability	2189	usd
CY2022Q4	us-gaap	Asset Acquisition Contingent Consideration Liability AssetAcquisitionContingentConsiderationLiability	198307	usd
CY2022	hlyk	Contingent Acquisition Consideration Long Term Portion ContingentAcquisitionConsiderationLongTermPortion	-98239	usd
CY2023Q4	us-gaap	Asset Acquisition Contingent Consideration Liability Current AssetAcquisitionContingentConsiderationLiabilityCurrent	2189	usd
CY2022Q4	us-gaap	Asset Acquisition Contingent Consideration Liability Current AssetAcquisitionContingentConsiderationLiabilityCurrent	100068	usd
CY2023	us-gaap	Asset Acquisition Consideration Transferred Contingent Consideration AssetAcquisitionConsiderationTransferredContingentConsideration	11094	usd
CY2022	us-gaap	Asset Acquisition Consideration Transferred Contingent Consideration AssetAcquisitionConsiderationTransferredContingentConsideration	779999	usd
CY2019Q2	us-gaap	Noncash Or Part Noncash Acquisition Interest Acquired1 NoncashOrPartNoncashAcquisitionInterestAcquired1	1	pure
CY2019Q2	us-gaap	Interest Earning Assets Average Amount Outstanding InterestEarningAssetsAverageAmountOutstanding	500000	usd
CY2019Q2	us-gaap	Contingent Consideration Classified As Equity Fair Value Disclosure ContingentConsiderationClassifiedAsEquityFairValueDisclosure	1764672	usd
CY2023	hlyk	Supplier Concentration SupplierConcentration	0.94	pure
CY2022	hlyk	Supplier Concentration SupplierConcentration	0.95	pure
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	528579	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	467994	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	335634	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	990	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	1333197	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	393778	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	939419	usd
CY2022Q3	us-gaap	Salaries And Wages SalariesAndWages	259000	usd
CY2022Q3	hlyk	Percentage Of Incentive Bonus PercentageOfIncentiveBonus	0.25	pure
CY2022Q3	us-gaap	Accrued Bonuses Current And Noncurrent AccruedBonusesCurrentAndNoncurrent	50000	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	100000	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	100000	shares
CY2023	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	10000000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.35	pure
CY2023Q4	us-gaap	Derivative Fixed Interest Rate DerivativeFixedInterestRate	0.21	pure
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-1012200	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-8815700	usd
CY2023	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-1012200	usd
CY2022	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-8815700	usd
CY2023	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-212600	usd
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-1851300	usd
CY2023	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	97700	usd
CY2022	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	576600	usd
CY2023	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-19500	usd
CY2022	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-214100	usd
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	102900	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	3747800	usd
CY2023	us-gaap	Income Tax Reconciliation Prior Year Income Taxes IncomeTaxReconciliationPriorYearIncomeTaxes	31500	usd
CY2022	us-gaap	Income Tax Reconciliation Prior Year Income Taxes IncomeTaxReconciliationPriorYearIncomeTaxes	-2259000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	9020200	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	8713000	usd
CY2023	us-gaap	Discontinued Operation Income Loss From Discontinued Operation During Phase Out Period Net Of Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax	-253800	usd
CY2023	us-gaap	Change In Unrealized Gain Loss On Fair Value Hedging Instruments1 ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1	-199300	usd
CY2022	us-gaap	Change In Unrealized Gain Loss On Fair Value Hedging Instruments1 ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1	-176600	usd
CY2023	hlyk	Gain From Change In Fair Value Of Contingent Acquisition Consideration GainFromChangeInFairValueOfContingentAcquisitionConsideration	-121000	usd
CY2022	hlyk	Gain From Change In Fair Value Of Contingent Acquisition Consideration GainFromChangeInFairValueOfContingentAcquisitionConsideration	-118300	usd
CY2023	hlyk	Loss From Change In Fair Value Of Debt LossFromChangeInFairValueOfDebt	93600	usd
CY2022	hlyk	Loss From Change In Fair Value Of Debt LossFromChangeInFairValueOfDebt	93600	usd
CY2023Q4	hlyk	Deferred Tax Asset Liabilities Right Of Use Lease Asset DeferredTaxAssetLiabilitiesRightOfUseLeaseAsset	-229500	usd
CY2022Q4	hlyk	Deferred Tax Asset Liabilities Right Of Use Lease Asset DeferredTaxAssetLiabilitiesRightOfUseLeaseAsset	-132500	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	230400	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	133000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	364500	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	290000	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	8905100	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	8802200	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	8905100	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	8802200	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	36800000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	35500000	usd
CY2023Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	3200000	usd
CY2023Q4	us-gaap	Tax Credit Carryforward Amount TaxCreditCarryforwardAmount	33600000	usd
CY2023	us-gaap	Revenues Revenues	5722379	usd
CY2023	us-gaap	Labor And Related Expense LaborAndRelatedExpense	3231117	usd
CY2023	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	2205085	usd
CY2023	hlyk	Cost Of Product Revenue CostOfProductRevenue	142501	usd
CY2023	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	3623402	usd
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	352027	usd
CY2023	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	319958	usd
CY2023	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	9874090	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-4151711	usd
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-145212	usd
CY2023	hlyk	Gain From Expiration Of Liability Classified Equity Instruments GainFromExpirationOfLiabilityClassifiedEquityInstruments	92641	usd
CY2023	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	427808	usd
CY2023	hlyk	Gain From Realization Of Contingent Sale Consideration Receivable GainFromRealizationOfContingentSaleConsiderationReceivable	1090857	usd
CY2023	hlyk	Gain Loss On Change In Fair Value Of Contingent Acquisition Consideration GainLossOnChangeInFairValueOfContingentAcquisitionConsideration	-11094	usd
CY2023	us-gaap	Interest Expense Other InterestExpenseOther	83812	usd
CY2022	us-gaap	Revenues Revenues	5858202	usd
CY2022	us-gaap	Labor And Related Expense LaborAndRelatedExpense	3335695	usd
CY2022	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	2566191	usd
CY2022	hlyk	Cost Of Product Revenue CostOfProductRevenue	463156	usd
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	4577490	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	829481	usd
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	2745563	usd
CY2022	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	14517576	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-8659374	usd
CY2022	us-gaap	Interest Expense Other InterestExpenseOther	22825	usd
CY2022	us-gaap	Financing Interest Expense FinancingInterestExpense	110000	usd
CY2022	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	55282	usd
CY2022	hlyk	Gain Loss On Change In Fair Value Of Contingent Acquisition Consideration GainLossOnChangeInFairValueOfContingentAcquisitionConsideration	-779999	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	2805902	usd
CY2022Q4	us-gaap	Goodwill Goodwill	319958	usd
CY2022Q4	us-gaap	Assets Held For Sale Not Part Of Disposal Group Current Other AssetsHeldForSaleNotPartOfDisposalGroupCurrentOther	1454856	usd
CY2023Q4	hlyk	Intercompany Sales IntercompanySales	790	usd
CY2022Q4	hlyk	Intercompany Sales IntercompanySales	790	usd
CY2023Q4	us-gaap	Contingent Consideration Classified As Equity Fair Value Disclosure ContingentConsiderationClassifiedAsEquityFairValueDisclosure	1663163	usd
CY2023Q4	us-gaap	Asset Acquisition Contingent Consideration Liability AssetAcquisitionContingentConsiderationLiability	2189	usd
CY2022Q4	us-gaap	Asset Acquisition Contingent Consideration Liability AssetAcquisitionContingentConsiderationLiability	198307	usd
CY2022Q4	us-gaap	Financial Instruments Sold Not Yet Purchased At Fair Value FinancialInstrumentsSoldNotYetPurchasedAtFairValue	75000	usd
CY2023Q4	us-gaap	Fair Value Net Asset Liability FairValueNetAssetLiability	2189	usd
CY2022Q4	us-gaap	Fair Value Net Asset Liability FairValueNetAssetLiability	273307	usd
CY2023	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	11094	usd
CY2022	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	779999	usd
CY2023	us-gaap	Proceeds From Sale Of Other Assets1 ProceedsFromSaleOfOtherAssets1	355000	usd
CY2023Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight	2500000	shares
CY2023	us-gaap	Warrant Exercise Price Decrease WarrantExercisePriceDecrease	0.17
CY2023Q4	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2022Q4	hlyk	Contingent Sale Consideration Receivable Current Portion ContingentSaleConsiderationReceivableCurrentPortion		usd
CY2023Q4	us-gaap	Assets Held For Sale Not Part Of Disposal Group Current AssetsHeldForSaleNotPartOfDisposalGroupCurrent		usd
CY2023Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent		usd
CY2023Q4	us-gaap	Other Long Term Debt Noncurrent OtherLongTermDebtNoncurrent		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2022	hlyk	Gain From Expiration Of Liability Classified Equity Instruments GainFromExpirationOfLiabilityClassifiedEquityInstruments		usd
CY2023	us-gaap	Financing Interest Expense FinancingInterestExpense		usd
CY2022	hlyk	Gain From Disposal Of Discontinued Operations GainFromDisposalOfDiscontinuedOperations		usd
CY2023	hlyk	Deemed Dividend Amortization Of Beneficial Conversion Feature DeemedDividendAmortizationOfBeneficialConversionFeature		usd
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised		usd
CY2022	hlyk	Gain From Disposal Of Discontinued Operation GainFromDisposalOfDiscontinuedOperation		usd
CY2022	hlyk	Gain From Expiration Of Liability Classified Equity Instruments GainFromExpirationOfLiabilityClassifiedEquityInstruments		usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation		usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2022	hlyk	Gain From Realization Of Contingent Sale Consideration Receivable GainFromRealizationOfContingentSaleConsiderationReceivable		usd
CY2023	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired		usd
CY2023	us-gaap	Payment For Contingent Consideration Liability Investing Activities PaymentForContingentConsiderationLiabilityInvestingActivities		usd
CY2022	hlyk	Proceeds From Sale Of Discontinued Operations ProceedsFromSaleOfDiscontinuedOperations		usd
CY2023	us-gaap	Cash Provided By Used In Investing Activities Discontinued Operations CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations		usd
CY2022	us-gaap	Cash Provided By Used In Investing Activities Discontinued Operations CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations		usd
CY2023	us-gaap	Cash Provided By Used In Financing Activities Discontinued Operations CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations		usd
CY2022	us-gaap	Cash Provided By Used In Financing Activities Discontinued Operations CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations		usd
CY2022	us-gaap	Income Taxes Paid IncomeTaxesPaid		usd
CY2022	hlyk	Fair Value Of Beneficial Conversion Feature Allocated To Proceeds Of Notes Payable FairValueOfBeneficialConversionFeatureAllocatedToProceedsOfNotesPayable		usd
CY2022	hlyk	Fair Value Of Warrants Issued To Extend Debt FairValueOfWarrantsIssuedToExtendDebt		usd
CY2022	hlyk	Warrant Liability Incurred In Connection With Collection Of Contingent Sale Consideration Receivable WarrantLiabilityIncurredInConnectionWithCollectionOfContingentSaleConsiderationReceivable		usd
CY2022	hlyk	Fair Value Of Shares Issued To Pay Vendor Accounts Payable Balance FairValueOfSharesIssuedToPayVendorAccountsPayableBalance		usd
CY2023	hlyk	Fair Value Of Shares Issued As Purchase Price Consideration FairValueOfSharesIssuedAsPurchasePriceConsideration		usd
CY2023Q4	us-gaap	Disposal Group Including Discontinued Operation Intangible Assets Current DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent		usd
CY2023Q4	us-gaap	Disposal Group Including Discontinued Operation Goodwill Current DisposalGroupIncludingDiscontinuedOperationGoodwillCurrent		usd
CY2023Q4	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent		usd
CY2023Q4	us-gaap	Disposal Group Including Discontinued Operation Other Current Liabilities DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities		usd
CY2023Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation		usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023Q4	hlyk	Deferred Equity Compensation Current DeferredEquityCompensationCurrent		usd
CY2022Q4	us-gaap	Accrued Sales Commission Current AccruedSalesCommissionCurrent		usd
CY2023Q4	hlyk	Accrued Warrant Liability Current AccruedWarrantLiabilityCurrent		usd
CY2023	hlyk	Contingent Acquisition Consideration Long Term Portion ContingentAcquisitionConsiderationLongTermPortion		usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign		usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign		usd
CY2023	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit		usd
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit		usd
CY2023	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit		usd
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit		usd
CY2023	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit		usd
CY2022	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit		usd
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit		usd
CY2023	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit		usd
CY2023	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit		usd
CY2023	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit		usd
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit		usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Discontinued Operation Income Loss From Discontinued Operation During Phase Out Period Net Of Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax		usd
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2022Q4	us-gaap	Contingent Consideration Classified As Equity Fair Value Disclosure ContingentConsiderationClassifiedAsEquityFairValueDisclosure		usd
CY2023Q4	us-gaap	Financial Instruments Sold Not Yet Purchased At Fair Value FinancialInstrumentsSoldNotYetPurchasedAtFairValue		usd
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001680139

Files In Submission

Name	View Source	Status
0001213900-24-028696-index-headers.html	Edgar Link	pending
0001213900-24-028696-index.html	Edgar Link	pending
0001213900-24-028696.txt	Edgar Link	pending
0001213900-24-028696-xbrl.zip	Edgar Link	pending
ea0201745-10k_health.htm	Edgar Link	pending
ea020174501ex21-1_health.htm	Edgar Link	pending
ea020174501ex23-1_health.htm	Edgar Link	pending
ea020174501ex31-1_health.htm	Edgar Link	pending
ea020174501ex31-2_health.htm	Edgar Link	pending
ea020174501ex32-1_health.htm	Edgar Link	pending
ea020174501ex32-2_health.htm	Edgar Link	pending
ex23-1_001.jpg	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
hlyk-20231231.xsd	Edgar Link	pending
image_001.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R100.htm	Edgar Link	pending
R101.htm	Edgar Link	pending
R102.htm	Edgar Link	pending
R103.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
hlyk-20231231_cal.xml	Edgar Link	unprocessable
hlyk-20231231_def.xml	Edgar Link	unprocessable
hlyk-20231231_lab.xml	Edgar Link	unprocessable
hlyk-20231231_pre.xml	Edgar Link	unprocessable
ea0201745-10k_health_htm.xml	Edgar Link	completed
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
R93.htm	Edgar Link	pending
R94.htm	Edgar Link	pending
R95.htm	Edgar Link	pending
R96.htm	Edgar Link	pending
R97.htm	Edgar Link	pending
R98.htm	Edgar Link	pending
R99.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$HLYK
HealthLynked Corp Stock $hlyk

2024 Q2 Form 10-K Financial Statement

#000121390024028696 Filed on April 01, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$HLYK HealthLynked Corp Stock $hlyk

2024 Q2 Form 10-K Financial Statement

#000121390024028696 Filed on April 01, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$HLYK
HealthLynked Corp Stock $hlyk